Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02535312 · OUTCOME

Number of Subject With Overall Response

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin · Source last updated 2026-07-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 8 weeks post-treatment

What was measured

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; Partial Response (PR), at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Overall Response (OR) = CR + PR

Groups in this outcome

Arm A, Dose Level 1 - 50mg TRC102, 60mg/m^2 Cisplatin (Phase I)

TRC102 50 mg/day PO days 1-4; Pemetrex 500 mg/m\^2 IV over 10 min day1; Cisplatin 60 mg/m\^2 IV over 30-60 min day1

Arm A, Dose Level 2 - 75mg TRC102, 60mg/m^2 Cisplatin (Phase I)

TRC102 75 mg/day PO days 1-4; Pemetrex 500 mg/m\^2 IV over 10 min day1; Cisplatin 60 mg/m\^2 IV over 30-60 min day1

Arm A, Dose Level 3 - 100mg TRC102, 60mg/m^2 Cisplatin (Phase I)

TRC102 100 mg/day PO days 1-4; Pemetrex 500 mg/m\^2 IV over 10 min day1; Cisplatin 60 mg/m\^2 IV over 30-60 min day1

Arm A, Dose Level 4 - 100mg TRC102, 75mg/m^2 Cisplatin (Phase I)

TRC102 100 mg/day PO days 1-4; Pemetrex 500 mg/m\^2 IV over 10 min day1; Cisplatin 75 mg/m\^2 IV over 30-60 min day1

Arm B, Dose Level 1 - 50mg TRC102 (Phase II)

TRC102 50 mg/day PO on days 1-4; Pemetrex 500mg/m\^2 IV over 10 min day 1

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A, Dose Level 1 - 50mg TRC102, 60mg/m^2 Cisplatin (Phase I)3
Arm A, Dose Level 2 - 75mg TRC102, 60mg/m^2 Cisplatin (Phase I)4
Arm A, Dose Level 3 - 100mg TRC102, 60mg/m^2 Cisplatin (Phase I)3
Arm A, Dose Level 4 - 100mg TRC102, 75mg/m^2 Cisplatin (Phase I)6
Arm B, Dose Level 1 - 50mg TRC102 (Phase II)14

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm A, Dose Level 1 - 50mg TRC102, 60mg/m^2 Cisplatin (Phase I)0Not reportedNot reportedNot reportedNot reported
Arm A, Dose Level 2 - 75mg TRC102, 60mg/m^2 Cisplatin (Phase I)1Not reportedNot reportedNot reportedNot reported
Arm A, Dose Level 3 - 100mg TRC102, 60mg/m^2 Cisplatin (Phase I)2Not reportedNot reportedNot reportedNot reported
Arm A, Dose Level 4 - 100mg TRC102, 75mg/m^2 Cisplatin (Phase I)0Not reportedNot reportedNot reportedNot reported
Arm B, Dose Level 1 - 50mg TRC102 (Phase II)1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        2
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      3
    4. group Id
      OG003
      value
      6
    5. group Id
      OG004
      value
      14
    units
    Participants
description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; Partial Response (PR), at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Overall Response (OR) = CR + PR
groups
  1. description
    TRC102 50 mg/day PO days 1-4; Pemetrex 500 mg/m\^2 IV over 10 min day1; Cisplatin 60 mg/m\^2 IV over 30-60 min day1
    id
    OG000
    title
    Arm A, Dose Level 1 - 50mg TRC102, 60mg/m^2 Cisplatin (Phase I)
  2. description
    TRC102 75 mg/day PO days 1-4; Pemetrex 500 mg/m\^2 IV over 10 min day1; Cisplatin 60 mg/m\^2 IV over 30-60 min day1
    id
    OG001
    title
    Arm A, Dose Level 2 - 75mg TRC102, 60mg/m^2 Cisplatin (Phase I)
  3. description
    TRC102 100 mg/day PO days 1-4; Pemetrex 500 mg/m\^2 IV over 10 min day1; Cisplatin 60 mg/m\^2 IV over 30-60 min day1
    id
    OG002
    title
    Arm A, Dose Level 3 - 100mg TRC102, 60mg/m^2 Cisplatin (Phase I)
  4. description
    TRC102 100 mg/day PO days 1-4; Pemetrex 500 mg/m\^2 IV over 10 min day1; Cisplatin 75 mg/m\^2 IV over 30-60 min day1
    id
    OG003
    title
    Arm A, Dose Level 4 - 100mg TRC102, 75mg/m^2 Cisplatin (Phase I)
  5. description
    TRC102 50 mg/day PO on days 1-4; Pemetrex 500mg/m\^2 IV over 10 min day 1
    id
    OG004
    title
    Arm B, Dose Level 1 - 50mg TRC102 (Phase II)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Up to 8 weeks post-treatment
title
Number of Subject With Overall Response
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice